Available online at www.sciencedirect.com

Bioorganic & Medicinal Chemistry Letters 18 (2008) 694­699

a,b-Cyclic-b-benzamido hydroxamic acids: Novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-a converting enzyme (TACE)
Gregory R. Ott,* Naoyuki Asakawa, Zhonghui Lu, Rui-Qin Liu, Maryanne B. Covington, Krishna Vaddi, Mingxin Qian, Robert C. Newton, David D. Christ, James M. Traskos, Carl P. Decicco and James J.-W. Duan
Department of Discovery Chemistry and Discovery Biology, Bristol-Myers Squibb Research and Development, Route 206 and Province Line Road, Princeton, NJ 08543-4000, USA
Received 17 October 2007; revised 14 November 2007; accepted 15 November 2007 Available online 21 November 2007

Abstract--Selective inhibitors of TNF-a Converting Enzyme (TACE) based on (1R,2S)-cyclopentyl, (3S,4S)-pyrrolidinyl, and (3R,4S)-tetrahydrofuranyl b-benzamido hydroxamic acids have been synthesized and evaluated. This study has led to the discovery of novel inhibitors whose profiles include activity against TACE in an enzyme assay, potency in the suppression of LPS-stimulated TNF-a in human whole blood, selectivity against a panel of MMPs and oral bioavailability. Ó 2007 Elsevier Ltd. All rights reserved.

The dysregulation of members of the ADAM (A Disintigrin and Metalloprotease) and MMP (matrix metalloprotease) family, zinc-dependent proteolytic enzymes belonging to the metzincin superfamily, has been implicated in numerous pathological conditions including cancer, osteoarthritis, and rheumatoid arthritis.1 Accordingly, small molecule inhibitors of MMPs and ADAMs have been extensively investigated as potential therapies.2 In particular, ADAM-17, also known as TNF-a Converting Enzyme or TACE, has garnered considerable attention as the sheddase responsible for controlling the amount of circulating TNF-a.3 The anti-TNF biologics entaneracept, inflixamab and adalimumab have validated the modulation of TNF-a clinically.4 Thus, as an alternative mediator of TNF-a, small molecule inhibitors of TACE have been widely researched.5 Furthermore, selective inhibitors are considered necessary since broad-based MMP inhibitors have led to negative clinical side effects.6 Though distinct from the standpoint of the overall sequence homology,

the MMPs and TACE have very similar active sites.7 We8 and others9 have recognized the S1' pockets of these enzymes as unique elements and we have used these features to construct homology models for insights into designing selective inhibitors.10 Recent efforts from these laboratories directed toward the search for small molecule, non-peptidic inhibitors of TACE and MMPs have led to the discovery of several novel templates.11 Efforts to further expand the structural diversity, selectivity profile and in vivo properties of these inhibitors have led to the discovery of constrained b-benzamido hydroxamic acid derivatives.12a Beyond pre-organization of the pharmacologically relevant moieties (i.e. hydroxamic acid, carbonyl and P1' groups), the constrained b-amino acid may impart distinct advantages noted for other b-peptides.13 The purported molecular interactions of the cis-a,b-cyclic-bamido hydroxamates are shown in Figure 1.12a The 4((2-methylquinolin-4-yl)methoxy)phenyl P1' moiety was optimized for potency and selectivity on earlier scaffolds, was successfully migrated to the b-amino acid scaffold, and remains constant for this study of TACE inhibitors. Herein we report the synthesis and evaluation of novel TACE inhibitors based upon cis-a,b-cyclic-bbenzamido hydroxamic acids, with focus on five-membered ring motifs including substituted (1R,2S)-cyclo-

Keywords: TNF-a; Tumor necrosis factor-a converting enzyme; TACE; Matrix metalloproteinase; MMP; b-amino acid. * Corresponding author at present address: Cephalon, Inc. 145 Brandywine Parkway, West Chester, PA 19380, USA. Tel.: +1 610 738 6861; fax: +1 610 738 6558; e-mail: gott@cephalon.com 0960-894X/$ - see front matter Ó 2007 Elsevier Ltd. All rights reserved. doi:10.1016/j.bmcl.2007.11.059

G. R. Ott et al. / Bioorg. Med. Chem. Lett. 18 (2008) 694­699

695

Figure 1. cis-a,b-cyclic-b-benzamido hydroxamic acid TACE inhibitors.

pentyl, (3S,4S)-pyrrolidinyl and (3R,4S)-tetrahydrofuranyl scaffolds. The requisite relative and absolute stereochemistry of the (1R,2S)-cyclopentane b-benzamido acid core is derived from the commercially available (1R,2S)-2-methyl cyclohex-4-ene-1,2-dicarboxylate. The benzyl ester 2 (Scheme 1) undergoes an oxidative cleavage-decarboxylative cyclization procedure to afford 3.14,15 Ketone protection was followed by unmasking of the acid. Curtius rearrangement16 of 5 installed the protected amine 6. Removal of the Cbz-group followed by coupling to 812a afforded the amide 9. Deketalization gave the common precursor 11a suitable for analogue preparation. Reduction, reductive amination, and fluorination proceeded smoothly to give 11b­e. Formation of the hydroxamic acid entailed treating the ester with a solution of hydroxylamine hydrochloride, methanol, and potassium hydroxide. The racemic pyrrolidine dicarboxylate 14 arises from an azo-methine-ylid [3+2] cycloaddition of benzylglycine to benzyl methyl maleate 13 (Scheme 2).17 Global debenzy-

lation and reprotection of the amine gave 16. Again, the protected b-amino ester 17 arises from a Curtius rearrangement. The free amine 18 was unmasked and coupled to give 19. Preparative HPLC separation of the enantiomers at this stage gave the desired (3S,4S)-enantiomer. The derived secondary amine common precursor 20a was converted to a variety of functionality including tertiary amine, sulfonamide, carbamate, and amide prior to hydroxamic acid formation. The tetrahydrofuranyl scaffold resulted from a diastereoselective reduction of an appropriate enamine18 (Scheme 3) derived from b-ketoester 22.19 The literature conditions, when applied to 23, gave the reduction product 24 as an inseparable 3:1 mixture of diastereomers. Debenzylation gave the free amine 25. Chiral HPLC analysis of 26 revealed an enantiomeric excess of 52%; the enantiomers were separated on preparative scale. The desired (3R,4S)-enantiomer was converted to 27. The (1R,2S)-cyclopentane b-amido hydroxamic analogue 1 provided the launching point for further optimization20 since 1 displayed excellent in vivo properties,

Scheme 1. Reagents and conditions: (a) KMnO4, H2O (99%); (b) AcOH, NaOAc (62%); (c) ethylene glycol, p-TsOH, C6H6 (95%); (d) H2, Pd(OH)2/ C, EtOAc (99%); (e) EtO2CCl, TEA; NaN3, H2O; benzene, reflux; BnOH, p-TsOH, reflux (60%); (f) BOP reagent, DIPEA, DMF (99%); (g) 3 N HCl, THF; (h) NaBH4, MeOH; (i) Me2NH, NaBH(OAc)3; (j) Et2NSF3, CH2Cl2; (k) NH2OH, KOH, MeOH; (l) TFA, CH2Cl2 (99%).

696

G. R. Ott et al. / Bioorg. Med. Chem. Lett. 18 (2008) 694­699

Scheme 2. Reagents and conditions: (a) N-benzylglycine, (HCHO)n, toluene, reflux (61%); (b) H2, Pd(OH)2/C, MeOH (79­99%) (c) BOC2O, NaOH (96%); (d) DPPA, TEA, BnOH (73%); (e) 8, BOP, DIPEA, DMF; HPLC separation of enantiomers (30%, >95% ee); (f) TFA, CH2Cl2 (100%); (g) aldehyde, DIPEA, CH2Cl2, NaBH(OAc)3; (h) acyl chloride, DIPEA, CH2Cl2; (i) sulfonyl chloride, DIPEA, CH2Cl2; (j) alkyl halide, TEA, CH2Cl2; (k) NH2OH, KOH, MeOH.

boost in cellular potency ($20-fold for 10 vs. parent 1). The ketone and hydroxyl substituted analogues (12a­c) were also potent in the WBA. The insertion of a difluoromethylene (12e) as an oxygen isostere22 provided only a moderate improvement relative to 1. Unfortunately, the addition of these substituents adversely impacted the Caco-2 permeability with the exception of the 1,3dioxolane analogue 10 (Papp = 1.8 · 10À6 cm/s); the acid labile nature of the 1,3-dioxolane precluded further advancement. Incorporation of polar functionality into the constrained b-amino acid ring system proved to be a successful tactic. A boost in cellular potency was realized with the pyrrolidine analogue 21a. The addition of either a sulfonyl or acetyl substituent (21b, 21c) did not alter cell potency. Permeability was low for both analogues and consistent with that result, 21b showed poor oral bioavailabilty (3%). By altering the nitrogen substituent, we could modulate both cell potency (21d) and permeability (21g). Toward achieving an optimal balance between potency and permeability, a variety of tertiary alkyl amines were evaluated. Analogues with increased lipophilicity (21i) provided inroads with respect to permeability (Papp = 1.3 · 10À6 cm/s) while maintaining potency in the desired range (IC50 = 196 nM). As the size and lipophilicity of the alkyl substituent increased, a slight erosion in cellular potency was observed. Unsaturated groups proved advantageous; 2-methylallyl and propargyl derivatives 21l and 21m gave suitable potency as well as permeability. Importantly, 21m displayed oral bioavailability in rat (Table 3, F = 25%). Cycloalkyl attachments or aromatic substituents (21n­p) provided no benefit. Similar to the pyrrolidine motif, (3R,4S)-tetrahydrofuranyl analogue 27, displayed excellent potency in the cellular assay (WBA IC50 = 33 nM), acceptable

Scheme 3. Reagents and conditions: (a) (R)-a-methylbenzyl amine, Yb(OTf)3, tol, reflux (48%); (b) NaBH(OAc)3, AcOH, CH3CN (36%, 3:1 mixture of diastereomers); (c) H2, Pd(OH)2/C, MeOH (100%); (d) 8, BOP Reagent, DIPEA, DMF; HPLC separation of enantiomers; (e) NH2OH, KOH, MeOH.

most notably oral bioavailability (F = 68% in dogs).12a Since TACE maturation and localization occurs intracellularly and that intracellular TACE is proteolytically active,21 the initial objective centered on improving the moderate potency in the suppression of TNF-a in the human whole blood assay (WBA, IC50 = 475 nM). Prior experience suggested that increasing the polarity of the molecule would drive potency into the desired range (IC50 < 200 nM). Modeling predicted that the b-amino acid ring carbons were solvent exposed, thus, this region was attractive for manipulation. We were gratified to find that the modifications to the 4position of the scaffold led to retention of TACE activity (Table 1, 10, 12a­e) and importantly, added a significant

G. R. Ott et al. / Bioorg. Med. Chem. Lett. 18 (2008) 694­699 Table 1. In vitro data for 1, 10, 12a­e, 21a­p, 27

697

Ex 1 10 12a 12b 12c 12d 12e 21a 21b 21c 21d 21e 21f 21g 21h 21i 21j 21k 21l 21m 21n 21o 21p 27
a b

X ­CH2­ C[-O(CH2)2O-] ­C(O)­[a-OH]­ ­CH[b-OH]­ ­CH[a-NMe2]­ ­CF2­ N­H N­Ms N­Ac NC(O)­i-Pr N­Piv N­C(O)OCH3 N­C(O)O­i-Pr N­Me N­i-Pr N­i-butyl N­Allyl N­(2-Methylallyl) N­2-Propynyl N­c-Bu N­Bn N­CH2(2-furanyl) O

pTACEa (IC50, nM) 1.0 1.0 1.8 2.3 4.6 <1.0 6.3 6.3 1.6 1.3 2.1 2.7 1.0 1.5 1.6 0.4 1.1 0.94 1.5 0.14 1.0 1.6 2.0 1.0

WBAb (IC50, nM) 475 24 76 46 121 193 301 75 79 66 68 196 223 403 50 165 254 97 210 109 191 880 320 33

MMP-1 (Ki, nM) >4948 >4948 >4948 >4948 >4948 >4948 >4948 >4948 >4948 >4948 >4948 >4948 >4948 >4948 >4948 >4948 >4948 >4948 >4948 >4948 >4948 >4948 >4948 >4948

MMP-2 (Ki, nM) >3333 2800 >3333 >3333 >3333 >3333 >3333 >3333 >3333 1700 >3333 >3333 2733 1500 >3333 >3333 >3333 >3333 >3333 >3333 >3333 2633 >3333 >3333

MMP-9 (Ki, nM) >2128 >2128 >2128 >2128 >2128 >2128 >2128 >2128 >2128 >2128 >2128 >2128 >2128 1851 >2128 >2128 >2128 >2128 >2128 >2128 >2128 >2128 >2128 >2128

Pappc (· 10À6 cm/s) 6.0 1.8 0.2 0.1 0.1 0.1 0.0 ­d 0.3 0.2 0.1 0.3 0.4 1.7 0.2 1.3 0.3 0.1 9.8 3.2 0.1 -- 1.1 1.0

pTACE IC50 and MMP Ki values are from a single determination. Inhibition of TNF-a release in WBA was determined with three donors. c Papp (A ! B) · 10À6 cm/s. d --: Not determined.

Table 2. Selectivity profilesa Enzyme pTACE (IC50) MMP-1 MMP-2 MMP-3 MMP-7 MMP-8 MMP-9 MMP-10 MMP-12 MMP-13 MMP-14 MMP-15
a

Table 3. Rat pharmacokinetic parametersa 21m (Ki, nM) 0.14 >5000 1120 54 6 2000 1720 240 12 490 2800 >7100 IV PK parameters dose (mg/kg) t1/2 (h) Cl (L/h/kg) Vss (L/kg) AUC (nM · h) dose (mg/kg) t1/2 (h) AUC (nM · h) F% 21mb 3.3 2.9 3.3 1.7 2234 3.3 3.1 567 25% 27c 5.0 2.1 2.3 0.8 4061 5.0 2.9 846 21%

PO

a

Determination of 3 for each dosing group, average value. Determined from discrete dosing. c Determined from n-in-1 cassette dosing.
b

pTACE IC50 and MMP Ki values are from a single determination.

permeability, and oral bioavailability in rats (Table 3, F = 21%). Indicative of inhibitors in this series, the selectivity profile of 21m against a panel of MMPs is shown in Table 2. Inhibitor 21m displays excellent selectivity (>1000-fold) for MMPs-1,-2,-8,-9,-10,-13,-14,-15. Activity was, how-

ever, evident for MMPs-3,-7,-12. The full pharmacokinetic parameters for lead heterocyclic inhibitors 21m (pyrrolidinyl) and 27 (tetrahydrofuranyl) are listed in Table 3. Both display relatively low clearance and >20% oral bioavailability. Of note, oral half-lives are >2 h for each analog. In summary, we have evaluated (1R,2S)-cyclopentanyl, (3S,4S)-pyrrolidinyl, and (3R,4S)-tetrahydrofuranyl b-

698

G. R. Ott et al. / Bioorg. Med. Chem. Lett. 18 (2008) 694­699

benzamido hydroxamic acids as privileged templates for the discovery of selective inhibitors of TACE. In particular, inhibitors 21m and 27 proved to be potent for pTACE, selective over a panel of MMPs, potent in the suppression of LPS-induced TNF-a in human whole blood and orally bioavailable. Acknowledgments We thank John Giannaras, Sherrill Nurnberg, and Paul Strzemienski for assistance in running in vitro assays, Bernice Brogdon, Bing Lu, Hang Zheng, and Jingtao Wu for assistance in pharmacokinetic studies and Maria Ribadeneira for Caco-2 assay. The authors thank Sarah Traeger and Tom Scholz for NMR analysis, Al Mical for chiral HPLC separation of intermediates, and George Emmett for intermediate preparation. References and notes
1. (a) Stocker, W.; Grams, F.; Baumann, U.; Reinemer, P.; Gomis-Ruth, F.-X.; McKay, D. B.; Bode, W. Protein Sci. 1995, 4, 823; (b) Hooper, N. M. FEBS Lett. 1994, 354, 1. 2. For recent reviews see (a) Skiles, J. W.; Gonnella, N. C.; Jeng, A. Y. Curr. Med. Chem. 2004, 11, 2911; (b) Skiles, J. W.; Gonnella, N. C.; Jeng, A. Y. Curr. Med. Chem. 2001, 8(4), 425; (c) Moss, M. L.; White, J. M.; Lambert, M. H.; Andrews, R. C. Drug Discovery Today 2001, 6(8), 417. 3. Black, R. A. Int. J. Biochem. Cell Biol. 2002, 34(1), 1. 4. (a) Moreland, L. W.; Baumgartner, S. W.; Schiff, M. H.; Tindall, E. A.; Fleischmann, R. M.; Weaver, A. L.; Ettlinger, R. E.; Cohen, S.; Koopman, W. J.; Mohler, K.; Widmer, M. B.; Blosch, C. M. N. Engl. J. Med. 1997, 337, 141; (b) Lipsky, P. E.; van der Heijde, D. M. F. M. E.; Clair, W. St.; Furst, D. E.; Breedveld, F. C.; Kalden, J. R.; Smolen, J. S.; Weisman, M.; Emery, P.; Feldmann, M.; Harriman, G. R.; Maini, R. N. N. Engl. J. Med. 2000, 343, 1594; (c) Machold, K. P.; Smolen, J. S. Exp. Opin. Bio. Ther. 2003, 3, 351. 5. For a recent review see Skotnicki, J. S.; Levin, J. I. Ann. Rep. Med. Chem. 2003, 38, 153. 6. Levitt, N. C.; Eskens, F. A. L. M.; O'Byrne, K. J.; Propper, D. J.; Denis, L. J.; Owen, S. J.; Choi, L.; Foekens, J. A.; Wilner, S.; Wood, J. M.; Nakajima, M.; Talbot, D. C.; Steward, W. P.; Harris, A. L.; Verweij, J. Clin. Cancer Res. 2001, 7, 1912. 7. Maskos, K.; Fernandez-Catalan, C.; Huber, R.; Bourenkov, G. P.; Bartunik, H.; Ellestad, G. A.; Reddy, P.; Wolfson, M. F.; Rauch, C. T.; Castner, B. J.; Davis, R.; Clarke, H. R. G.; Petersen, M.; Fitzner, J. N.; Douglas, P. C.; March, C. J.; Paxton, R. J.; Black, R. A.; Bode, W. Proc. Natl. Acad. Sci. U.S.A. 1998, 95(7), 3408. 8. Wasserman, Z. R.; Duan, J. J.-W.; Voss, M. E.; Xue, C.-B.; Cherney, R. J.; Nelson, D. J.; Hardman, K. D.; Decicco, C. P. Chem. & Biol. 2003, 10(3), 215. 9. For leading references see (a) Chen, J. M.; Jin, G.; Sung, A.; Levin, J. I. Bioorg. Med. Chem. Lett. 2002, 12, 1195; (b) Robinson, R. P.; Laird, E. R.; Blake, J. F.; Bordner, J.; Donahue, K. M.; Lopresti-Morrow, L. L.; Mitchell, P. G.; Reese, M. R.; Reeves, L. M.; Stam, E. J.; Yocum, S. A. J. Med. Chem. 2000, 43, 2229.

10. Recently, other potential avenues for design of selective TACE inhibitors have been reported, see Lukacova, V.; Zhang, Y.; Kroll, D. M.; Raha, S.; Comez, D.; Balaz, S. A. J. Med. Chem. 2005, 48, 2361. 11. For leading references see (a) Xue, C.-B.; Voss, M. E.; Nelson, D. J.; Duan, J. J.-W.; Cherney, R. J.; Jacobson, I. C.; He, X.; Roderick, J.; Chen, L.; Corbett, R. L.; Wang, L.; Meyer, D. T.; Kennedy, K.; DeGrado, W. F.; Hardman, K. D.; Teleha, C. A.; Jaffee, B. D.; Liu, R.-Q.; Copeland, R. A.; Covington, M. B.; Christ, D. D.; Trzaskos, J. M.; Newton, R. C.; Magolda, R. L.; Wexler, R. R.; Decicco, C. P. J. Med. Chem. 2001, 44, 2636; (b) Duan, J. J.-W.; Chen, L.; Wasserman, Z. R.; Lu, Z.; Liu, R.-Q.; Covington, M. B.; Qian, M.; Hardman, K. D.; Magolda, R. L.; Newton, R. C.; Christ, D. D.; Wexler, R. R.; Decicco, C. P. J. Med. Chem. 2002, 45, 4954; (c) Xue, C.-B.; He, X.; Roderick, J.; Corbett, R. L.; Duan, J. J.-W.; Liu, R.-Q.; Covington, M. B.; Newton, R. C.; Trzaskos, J. M.; Magolda, R. L.; Wexler, R. R.; Decicco, C. P. Bioorg. Med. Chem. Lett. 2003, 13(24), 4293; (d) Xue, C.-B.; Chen, X. T.; He, X.; Roderick, J.; Corbett, R. L.; Ghavimi, B.; Liu, R.-Q.; Covington, M. B.; Qian, M.; Ribadeneira, M. D.; Vaddi, K.; Trzaskos, J.; Newton, R. C.; Duan, J. J.-W.; Decicco, C. P. Bioorg. Med. Chem. Lett. 2004, 14, 4453; (e) Gilmore, J. L.; King, B. W.; Harris, C.; Maduskuie, T.; Mercer, S. E.; Liu, R.-Q.; Covington, M. B.; Qian, M.; Ribadeneria, R.; Vaddi, K.; Trzaskos, J. M.; Newton, R. C.; Decicco, C. P.; Duan, J. J.-W. Bioorg.Med. Chem. Lett. 2006, 16, 2699; (f) Cherney, R. J.; Mo, R.; Meyer, D. T.; Hardman, K. D.; Liu, R.-Q.; Covington, M. B.; Qian, M.; Wasserman, Z. R.; Christ, D. D.; Trzaskos, J. M.; Newton, R. C.; Decicco, C. P. J. Med. Chem. 2004, 47, 2981. 12. For preliminary accounts of this work see: (a) Duan, J. J.W.; Chen, L.; Lu, Z.; Xue, C.-B.; Liu, R.-Q.; Covington, M. B.; Qian, M.; Wasserman, Z. R.; Vaddi, K.; Christ, D. D.; Trzaskos, J. M.; Newton, R. C.; Decicco, C. P. Bioorg. Med. Chem. Lett. 2007. doi:10.1016/j.bmcl.2007.10.093; (b) Ott, G. R.; Lu, Z.; Asakawa, N.; Covington, M. B.; Qian, M.; Liu, R.-Q.; Newton, R. C.; Christ, D. D.; Decicco, C. P.; Duan, J. J.-W. Abstracts of Papers, 228th ACS National Meeting, Philadelphia, PA, USA, 2004, August 22­26, MEDI-324; (c) Chen, X.-T.; Ghavimi, B.; Corbett, R. L.; Xue, C.-B.; Liu, R.-Q.; Covington, M. B.; Qian, M.; Vaddi, K. G.; Christ, D. D.; Hartman, K. D.; Ribadeneira, M. D.; Trzaskos, J. M.; Newton, R. C.; Decicco, C. P.; Duan, J. J.-W. Bioorg. Med. Chem. Lett. 2007, 17(7), 1865. 13. Seebach, D.; Beck, A. K.; Bierbaum, D. Chem. Biodiv. 2004, 1(8), 1111. 14. All intermediates are in accordance with their 1H NMR and mass spectrometry data. In addition, all final targets are consistent with 1H NMR, high resolution mass spectrometry and combustion analysis. 15. For a similar sequences, see: (a) Gais, H. J.; Buelow, G.; Zatorski, A.; Jentsch, M.; Maidonis, P.; Hemmerle, H. J. Org. Chem. 1989, 54, 5115; (b) Cheetham, R.; Deo, P.; Lawson, K.; Moseley, D.; Mound, R.; Pilkington, B. Pest. Sci. 1997, 50, 329. 16. For examples of cyclic b-amino acids prepared using a Curtius rearrangement, see: Bolm, C.; Schiffers, I.; Atodiresei, I.; Hackenberger, C. P. R. Tetrahedron: Asymmetry 2003, 14, 3455. 17. (a) Grigg, R.; Thianpatanagul, S. J. Chem. Soc. Chem. Commun. 1984, 180; (b) Joucia, M.; Mortier, J. J. Chem. Soc., Chem. Commun. 1985, 1566. 18. Cimarelli, C.; Palmieri, G. J. Org. Chem. 1996, 61(16), 5557.

G. R. Ott et al. / Bioorg. Med. Chem. Lett. 18 (2008) 694­699

699

19. Dowd, P.; Choi, S.-C. Tetrahedron Lett. 1989, 30, 6129. 20. Details of the pTACE (porcine TACE), MMP, human whole blood (WBA) assays have been reported, see Ref. 11a. Porcine TACE was used due to availability and homology to human TACE.

21. (a) Schlondorff, J.; Becherer, J. D.; Blobel, C. P. Biochem. J. 2000, 347, 131; (b) Solomon, K. A.; Covington, M. B.; DeCicco, C. P.; Newton, R. C. J. Immunol. 1997, 159, 4524. 22. For a review article see O'Hagen, D.; Rsepa, H. S. Chem. Commun. 1997, 645.

